TY - JOUR T1 - Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.122.264946 SP - jnumed.122.264946 AU - Lisa M. Gudenkauf AU - Melody Chavez AU - Melinda L. Maconi AU - Carley Geiss AU - Ameen Seyedroudbari AU - Pan Thin AU - Aasha I. Hoogland AU - Kathleen Nguyen AU - Vishnu Murthy AU - Wesley R. Armstrong AU - Khaled Komrokji AU - Laura B. Oswald AU - Heather S.L. Jim AU - Ghassan El-Haddad AU - Wolfgang Peter Fendler AU - Ken Herrmann AU - David Cella AU - Johannes Czernin AU - Michael S. Hofman AU - Adam P. Dicker AU - Jeremie Calais AU - Scott T. Tagawa AU - Brian D. Gonzalez Y1 - 2023/01/01 UR - http://jnm.snmjournals.org/content/early/2023/01/12/jnumed.122.264946.abstract N2 - The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly with recent FDA approval of the first Lutetium-177-PSMA-ligand. Current patient-reported outcomes (PRO) measures were designed to assess impacts of chemotherapy or surgery. We aimed to develop the first PRO measure for PC patients receiving RNT. Methods: First, we identified relevant symptoms/toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the FACT-RNT with patient input. Results: This multi-step process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The Functional Assessment of Cancer Therapy – Radionuclide Therapy (FACT-RNT) is a new standardized tool to monitor relevant symptoms/toxicities in RNT trials and real-world settings. ER -